Sign in →

Test Code LAB5054 Chromogranin A, Serum

Important Note

Mayo's test code: CGAK

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Reporting Name

Chromogranin A, S

Specimen Type

Serum


Specimen Required


Patient Preparation: For at least 2 weeks before specimen collection, patient should stop taking proton pump inhibitor medications.

Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL

Collection Information: Centrifuge and aliquot serum into plastic vial. Do not submit in original tube.


Reject Due To

Gross hemolysis Reject
Gross lipemia OK
Gross icterus OK

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Frozen (preferred) 90 days
  Ambient  48 hours
  Refrigerated  48 hours

Specimen Minimum Volume

0.2 mL

Day(s) Performed

Monday through Saturday

Specimen Retention Time

2 weeks

Report Available

1 to 3 days

Reference Values

<93 ng/mL

Reference values apply to all ages.

Useful For

Aiding in monitoring disease progression during the course of disease and treatment in patients with gastroenteropancreatic neuroendocrine tumors (grade 1 and grade 2) when used in conjunction with other clinical methods

 

This test is not indicated for use as a stand-alone monitoring assay.

CPT Code Information

86316

LOINC Code Information

Test ID Test Order Name Order LOINC Value
CGAK Chromogranin A, S 9811-1

 

Result ID Test Result Name Result LOINC Value
CGAK Chromogranin A, S 9811-1

Supportive Data

Reference values were derived from 162 donors (68 [42%] male and 94 [58%] female), ages 21 to 79. There was no age (p>0.17) or sex (p>0.85) association at the 97.5th percentile, so the overall reference range of <93 ng/mL (97.5% CI: 86, 99) was calculated.

 

A previous study in 148 pediatric patients (F=66, M=82; age range 1 day to 18 years) demonstrated that there is no significant difference in serum chromogranin A concentrations between children and adults.

 

A prospective, multi-center, observational study with 153 evaluable neuroendocrine tumor patients was performed to validate the performance of B·R·A·H·M·S CgA (chromogranin A)II KRYPTOR assay in monitoring grade 1 and grade 2 GEP-NET progressive or non-progressive disease within 32 months.(9) Course of disease was assessed by standard imaging (CT/MRI scans) and tumors were classified by RECIST 1.1 criteria for progression (progressive disease) vs. no progression (complete response, partial response, or stable disease).

Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

-General Request (T239)

-Oncology Test Request (T729)